NALA-Drug Comparator study in HER2+ Metastatic Breast Cancer patients
Research type
Research Study
Full title
A STUDY OF NERATINIB PLUS CAPECITABINE VERSUS LAPATINIB PLUS CAPECITABINE IN PATIENTS WITH HER2+ METASTATIC BREAST CANCER WHO HAVE RECEIVED TWO OR MORE PRIOR HER2-DIRECTED REGIMENS IN THE METASTATIC SETTING (NALA)
IRAS ID
111478
Contact name
Stephen Chan
Contact email
Sponsor organisation
Puma Biotechnology, Inc.
Eudract number
2012-004492-38
Clinicaltrials.gov Identifier
REC name
East Midlands - Nottingham 2 Research Ethics Committee
REC reference
13/EM/0189
Date of REC Opinion
30 Jul 2013
REC opinion
Further Information Favourable Opinion